Greenyn Biotechnology , Ltd EBIT

The latest EBIT for 6846.TWO is $160M as of June 2026. That compares with $190M in the prior-year period — down 11.9% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Greenyn Biotechnology , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6846.TWO's EBIT moved from $190M to $160M — a 11.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Greenyn Biotechnology , Ltd's operating scale or balance-sheet position.

Against Healthcare companies, 6846.TWO currently prints $160M for EBIT, while the sector average sits near $130B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Greenyn Biotechnology , Ltd's growth, margins, and balance sheet.

A EBIT figure of $160M for 6846.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 6846.TWO's EBIT ($160M), review year-over-year change from $190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.